Washington/UNI/Sputnik: The benefits expected from the Pfizer Covid-19 vaccine shots for children between 5 and 11 years old outweigh the risks of side effects, the US Food and Drug Administration (FDA) said in a report.
New York: Two doses of Pfizer-BioNTech (BNT162b2) are 90% effective against COVID-19 hospitalizations for all variants, including delta, for at least six months, confirms a new study from Kaiser Permanente and Pfizer published in The Lancet.
New Delhi/IBNS: India would not buy Covid-19 vaccines from foreign producers Pfizer/BioNTech and Moderna as domestic production of the shots has increased manifold, Reuters reported citing sources.
New York: Pfizer Inc and BioNTech SE on Monday announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older.
New Delhi/IBNS: All US-based Covid-19 vaccine makers are insisting on protection from lawsuits and liability and India is reluctant to allow their entry on these conditions, delaying their availability in India, according to NK Arora, head of the government's vaccine panel.
London: Total antibody levels appear to start declining from as early as six weeks after complete vaccination and can reduce by more than 50% over 10 weeks, according to new data from UCL’s Virus Watch study.
New Delhi/IBNS: US pharma giant Pfizer, which is in the final stages of closing a coronavirus vaccine deal with the Indian government, has said its jab is very effective against the Delta variant of the virus, according to media reports.
Washington/Sputnik: No COVID-19 variant has escaped the protection of Pfizer's vaccine, but the company continues to monitor and test it against emerging strains around the world, CEO Albert Bourla said on Thursday.
Pfizer on Tuesday said it will begin testing its COVID-19 vaccine on a larger group of children under the age of 12.
New Delhi/IBNS: Amid the spread of the Delta variant of coronavirus, which is dominant in India, the gap between the two doses should be reduced and boosters must be provided to those whose immunity may not be high enough, The Lancet journal said in a new study.
New Delhi/IBNS: The Indian government has exempted "well established" foreign COVID-19 vaccines makers from any bridging clinical trials if it has been certified by the National Control Lab of the country where it is made, media reports said.
Moscow/Sputnik: The Japanese government approved Pfizer's COVID-19 vaccine for ages 12 to 15 on Monday, the media reported.
London/IBNS: Two doses of AstraZeneca vaccine or Pfizer vaccine can give more than 80 per cent protection from the B1.617.2 variant of coronavirus first found in India, a new study conducted by the UK government has revealed, media reports said.
Washinton/Sputnik: The US Food and Drug Administration (FDA) is preparing to approve the Pfizer-BioNTech COVID-19 vaccine for those aged 12 to 15, The New York Times reported, citing federal officials.
Pfizer is discussing with the Indian government expedited approval of its vaccine, company CEO Alber Bourla has said while announcing a donation of medicines worth $70 million to fight the resurgent pandemic.